“…[5] However, TAVR volume shows geographical heterogeneity due to national economic resources and investment in novel medical services, ranging from over 0.3 per million to 200 per million people. [6] Although the adoption of TAVR in Chinese mainland relatively lagged behind that of the Western world, increasing momentum has been presented, particularly in recent years, with a total of 22,783 cases by October 2022.…”